Change in Growth Differentiation Factor 15, but Not C-Reactive Protein, Independently Predicts Major Cardiac Events in Patients with Non-ST Elevation Acute Coronary Syndrome
Table 1
Clinical variables of non-ST-segment elevation acute coronary syndrome patients with and without MACE at 36-month followup.
Variable
MACE
P value
Yes ()
No ()
Age (years)
68 ± 11
66 ± 11
0.24
Men
25 (55.6%)
138 (65.7%)
0.23
Hypertension (>140/90 mmHg)
32 (71.1%)
133 (63.3%)
0.39
Hypercholesterolemia (>5.17 mmol/L)
19 (42.2%)
99 (47.1%)
0.62
Smokers
31 (68.9%)
121 (57.6%)
0.18
Diabetes
14 (31.1%)
75 (35.7%)
0.61
TIMI risk score
0.47
2
9 (20%)
35 (16.7%)
3
9 (20%)
74 (35.2%)
4
16 (35.6%)
58 (27.6%)
5
10 (22.2%)
38 (18.1%)
6
1 (2.2%)
5 (2.4%)
Coronary artery disease
0.35
1 vessel
22 (4.9%)
115 (54.8%)
2 vessel
13 (28.9%)
40 (19%)
3 vessel
9 (20%)
45 (21.4%)
LVEF (%)
54 ± 10
56 ± 12
0.22
Treatment at admission
Aspirin
45 (100%)
207 (98.6%)
0.9
Clopidogrel
39 (86.7%)
161 (76.7%)
0.16
Nitrates
44 (97.8%)
202 (96.2%)
0.9
Statins
45 (100%)
207 (98.6%)
0.9
Angiotensin-converting enzyme inhibitors
18 (40%)
68 (32.4%)
0.9
-Blockers
42 (93.3%)
191 (91%)
0.77
Biochemistry
Creatinine (mg/dL)
1.17 ± 0.25
1 ± 0.87
0.25
Total cholesterol (mmol/L)
4.05 ± 1.04
4.00 ± 1.18
0.48
Peak troponin I (ng/mL)
4.85 ± 0.16
4.39 ± 0.17
0.09
Data is expressed as mean ± standard deviation and number of patients (%) for categorical variables. MACE: major adverse cardiovascular events; LVEF: left ventricular ejection fraction.
